Checking up on checkpoint inhibitors

Blood. 2017 Jul 13;130(2):107-108. doi: 10.1182/blood-2017-05-783696.

Abstract

In this issue of Blood, Haverkos et al present timely and compelling data revealing both the opportunity and serious hazards incurred with the use of programmed death 1 (PD-1) pathway blockade after allogeneic hematopoietic cell transplant (allo-HCT) in relapsed lymphoma patients.

Publication types

  • Comment

MeSH terms

  • Checkpoint Kinase 2*
  • DNA Damage / drug effects*
  • Enzyme Inhibitors
  • Humans
  • Protein Kinase Inhibitors

Substances

  • Enzyme Inhibitors
  • Protein Kinase Inhibitors
  • Checkpoint Kinase 2